Combination Therapy Sequencing in Parkinson's Disease

V2, Crosslink

🧫

Combination Therapy Sequencing in Parkinson's Disease

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-combinat

🧫 Experiment Protocol Validationproposed

SUMMARY

# Combination Therapy Sequencing in Parkinson's Disease ## Background and Rationale This translational validation study systematically evaluates optimal sequencing and combination strategies for disease-modifying therapies in Parkinson's disease, addressing the critical clinical need for rational polytherapy approaches. The experiment employs both preclinical models and human biomarker studies to determine synergistic combinations of neuroprotective agents targeting complementary pathways includ

METHODOLOGY NOTES

**Phase 1: Patient Recruitment and Baseline Assessment (Weeks 1-4)** • Recruit 240 Parkinson's disease patients (Hoehn & Yahr stages 2-3) from multiple clinical centers • Obtain informed consent and verify inclusion criteria: age 50-75, confirmed PD diagnosis >2 years, stable on levodopa ≥3 months • Exclude patients with atypical parkinsonism, dementia (MoCA <26), or recent deep brain stimulation • Randomize patients into 4 groups (n=60 each): Group A (levodopa→dopamine agonist→MAO-B inhibitor), Group B (dopamine agonist→levodopa→MAO-B inhibitor), Group C (MAO-B inhibitor→levodopa→dopamine agonist), Group D (standard care control) • Conduct baseline assessments: UPDRS Parts I-IV, Parkinson's Disease Questionnaire-39 (PDQ-39), levodopa equivalent daily dose (LEDD), and motor fluctuation diary **Phase 2: First Treatment Intervention (Weeks 5-16)** • Initiate first therapy according to randomization sequence • Titrate medications over 4 weeks to optimal therapeutic dose based on clinical

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.904625Z'}
summary	# Combination Therapy Sequencing in Parkinson's Disease ## Background and Rationale This translational validation study systematically evaluates optimal sequencing and combination strategies for disea
entities	{'genes': ['ADRA2A/DNMT1/DRD2'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	validation
primary_outcome	Identification of at least three synergistic drug combinations showing >30% greater neuroprotection than individual agents in α-synuclein transgenic mice, with validated biomarker signatures predictin
methodology_notes	Phase 1: Patient Recruitment and Baseline Assessment (Weeks 1-4) • Recruit 240 Parkinson's disease patients (Hoehn & Yahr stages 2-3) from multiple clinical centers • Obtain informed consent and v
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.904631', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

730

Outgoing

653

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Combination Therapy Sequencing in Parkinson's Disease

derives from (13)

supports (4)

💬 Discussion